Breyanzi Purple Book BLA 125714

BLA number
125714
Proprietary names
Breyanzi
Proper names
lisocabtagene maraleucel
Applicant
Juno Therapeutics, Inc. a Bristol Myer-Squibb Company
Center
CBER
First observed release
2021-02-01
Latest observed release
2026-06-01
Newest archive release
2026-06-01
FDA patent list
No patents listed in the captured FDA patent list; source updated 2025-06-11
Coverage
Present in newest release

Latest Known Product Presentations#

Product, Proprietary name, Proper name table
ProductProprietary nameProper nameLicense typeStrengthDosage formRoutePresentationMarketingLicensureApprovalPatent list provided
001Breyanzilisocabtagene maraleucel351(a)4.6ML/VIALInjectionIntravenousSingle-Dose VialRxLicensed2021-02-05

Published Patent List#

No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.

Official Monthly Change Events#

Release, Event, Product table
ReleaseEventProductNameLicense typeStatusApplicant
2024-07-01U001Breyanzi351(a)RxJuno Therapeutics, Inc. a Bristol Myer-Squibb Company
2024-06-01U001Breyanzi351(a)RxJuno Therapeutics, Inc. a Bristol Myer-Squibb Company
2024-04-01U001Breyanzi351(a)RxJuno Therapeutics, Inc. a Bristol Myer-Squibb Company
2023-03-01U001Breyanzi351(a)RxJuno Therapeutics, Inc. a Bristol Myer-Squibb Company
2022-01-01U001Breyanzi351(a)RxJuno Therapeutics, Inc. a Bristol Myer-Squibb Company
2021-10-01U001Breyanzi351(a)RxJuno Therapeutics, Inc., a Bristol Myer-Squibb Company
2021-09-01U001Breyanzi351(a)RxJuno Therapeutics, a Celgene Company
2021-05-01U001Breyanzi351(a)RxJuno Therapeutics, a Celgene Company
2021-02-01N, U001Breyanzi351(a)RxJuno Therapeutics, a Celgene Company

Observed Product State History#

Release, Product, Name table
ReleaseProductNameLicense typeMarketingLicensureApproval
2021-02-01001Breyanzi351(a)RxLicensed2021-02-05